FULC
Fulcrum Therapeutics, Inc.
Biotechnology · Healthcare · United States
3.71
close · 2026-10-30
value
69
cheaper than peers69
quality
80
stronger fundamentals80
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | -0.9% | 98 |
| earnings yield, 1 year ago | -4.3% | 86 |
| price to book | 0.91× | 82 |
| EV to EBITDA | 0.24× | 81 |
| earnings yield, 2 years ago | -42.9% | 50 |
| earnings yield, latest year | -31.8% | 47 |
| cash flow yield, latest year | -21.3% | 45 |
| earnings yield, 3 years ago | -65.8% | 45 |
| cash flow yield, 2 years ago | -32.3% | 33 |
| cash flow yield, 3 years ago | -34.9% | 31 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -32.4% | 83 |
| debt to equity | 1.7% | 63 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $283M |
| free cash flow | -$37.4M |
| employees | 9 |
| first trade | 2019-07-18 |
| next earnings | not reported |
| fundamentals updated | 2026-08-18 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.18 | -0.16 | -1.59 | -2.44 |
| free cash flow | -$60.4M | -$2.5M | -$91.5M | -$99.0M |
| net income | -$74.9M | -$9.7M | -$97.3M | -$109.9M |
| revenue | $0 | $80.0M | $2.8M | $6.3M |
| unusual items | $0 | -$2.1M | $0 | -$427,000 |